Whole Body Health Sale

Life Extension Magazine

LE Magazine July 2007
image

Unfounded Fears Could Limit Prostate Cancer Treatment Options

image

The New England Journal of Medicine (NEJM) recently reported that cabergoline (Dostinex®), a drug commonly used as an adjuvant therapy for men with prostate cancer, may cause heart valve damage.*

Unfortunately, this report could cause oncologists to advise their patients to discontinue this helpful medication. Before prostate cancer specialists limit their patients’ treatment options, it is important that both they and their patients be aware that the drug doses associated with heart valve damage in the NEJM study were literally thousands of times higher than the cumulative lifetime dose typically taken by men with prostate cancer.

The drugs in question in the study—pergolide (Permax®) and cabergoline (Dostinex®)—are categorized as dopamine agonists, a class of drugs that increase production of the brain neurotransmitter dopamine while decreasing production of the pituitary hormone prolactin. Reducing prolactin can help avert the breast enlargement and tenderness that may occur as a side effect of various hormonal treatments for prostate cancer.

The NEJM study found that when patients with Parkinson’s disease received massive doses of cabergoline, they displayed signs of heart valve damage.* According to the study authors, these patients were exposed to a mean cumulative dose of cabergoline of 4015 mg.

Prostate cancer patients typically use vastly lower amounts of cabergoline than the dosage associated with heart valve damage in the NEJM study. A typical dose regimen for lowering prolactin in prostate cancer patients is 0.25 mg taken three times weekly, to a maximum of 0.5 mg three times weekly of cabergoline. Using even the latter dose (1.5 mg weekly), achieving the mean cumulative dose of 4015 mg associated with moderate to severe (grade 3-4) valve abnormalities cited in the NEJM study would take a prostate cancer patient more than 51 years! Even the lowest cumulative dose reported by the authors with this degree of valvular abnormality would take 10.3 years to occur at the 1.5 mg weekly dose of cabergoline. In fact, most prostate cancer patients take the maximum dose of 1.5 mg weekly for periods ranging from months to a few years. If we assume a five-year duration of therapy, this would equate with a cumulative dose of 390 mg, less than one tenth of the mean cumulative dose reported in the NEJM article.

For physicians to stop prescribing dopamine agonist drugs in their prostate cancer patients who are being treated for overproduction of prolactin would appear to reflect an overreaction and misreading of the NEJM study results. This is even more the case if patients receiving dopamine agonist drugs are monitored using a standard echocardiogram on an annual basis to document any cardiac valve abnormalities. In my practice, I have yet to see a prostate cancer patient with clinically significant valvular disease who has been on cabergoline as part of an anti-cancer treatment or to help reduce breast tenderness. In the few patients I have seen with trace to mild (grade 1-2) heart valve abnormalities per echocardiogram, a review of echocardiograms done prior to the initiation of cabergoline showed the same valvular findings.

The NEJM study results underscore that physicians must be mindful not to discard helpful therapies in the treatment of prostate cancer without a detailed review of the issues and context involved.

—Stephen B. Strum MD, FACP

Medical Oncologist Specializing in Prostate Cancer Ashland, Oregon

Reference

* Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007 Jan 4;356(1):39-46.

Green Tea May Lower Blood Sugar, Lipid Levels

image

Green tea extract lowers blood sugar and decreases blood lipid levels in diabetic rats, report scientists in India.* Excess blood sugar contributes directly to many of the damaging effects of diabetes, while elevated lipids are linked to increased risk of heart disease.

Rats with experimentally induced diabetes were treated with green tea extract; a control group did not receive the extract. After one month, the control rats were heavier and had higher levels of blood glucose and artery-clogging blood lipids—such as low-density lipoprotein (LDL) and triglycerides—than did the rats given green tea. The supplemented animals also had increases in beneficial high-density lipoprotein (HDL) and decreased levels of total cholesterol and blood sugar.

“Green tea can reduce the risk of cardiovascular disease in diabetes, with a significant improvement in lipid metabolism,” the investigators concluded.

—Dale Kiefer

Reference

* Anandh Babu PV, Sabitha KE, Shyamaladevi CS. Green tea extract impedes dyslipidaemia and development of cardiac dysfunction in streptozotocin-diabetic rats. Clin Exp Pharmacol Physiol. 2006 Dec;33(12):1184-9.

Pomegranate Extract Inhibits Lung Cancer in Mice

image

Pomegranate fruit extract significantly reduces the number and size of lung cancer tumors in mice, report scientists at the University of Wisconsin.*

The researchers gave one group of mice pomegranate fruit extract in their drinking water; a second group did not receive the extract. Both groups were then exposed to one or two known lung carcinogens. The number of tumors that developed in pomegranate-fed mice was reduced by up to 61% compared to control mice. The scientists also confirmed that various signaling chemicals ordinarily found among cancerous tumors were greatly inhibited in the pomegranate-treated mice.

Noting that the treated mice were given a “human-achievable dose” of pomegranate fruit extract, the scientists concluded that the extract markedly inhibits lung tumor development and “merits investigation as a chemopreventive agent for human lung cancer.”

—Dale Kiefer

Reference

* Khan N, Afaq F, Kweon MH, Kim K, Mukhtar H. Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res. 2007 Apr 1;67(7):3475-82.

Astaxanthin Reduces Exercise-Induced Fatigue

image

Japanese researchers say mice supplemented with the potent natural antioxidant astaxanthin appeared to burn fatty acids for fuel more efficiently, were able to exercise far longer, and had greatly decreased fat accumulation compared to mice that did not receive the compound.1

Previous research has shown that astaxanthin reduces oxidative damage from strenuous exercise in the skeletal and heart muscles of supplemented mice.2 Research also suggests that astaxanthin may improve human cardiovascular health and prevent cancer, among other potential benefits.3,4

Produced by certain marine algae, astaxanthin is a more potent antioxidant than other carotenes such as beta carotene.

—Dale Kiefer

Reference

1. Ikeuchi M, Koyama T, Takahashi J, Yazawa K. Effects of astaxanthin supplementation on exercise-induced fatigue in mice. Biol Pharm Bull. 2006 Oct;29(10):2106-10.
2. Aoi W, Naito Y, Sakuma K, et al. Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. Antioxid Redox Signal. 2003 Feb;5(1):139-44.
3. Higuera-Ciapara I, Felix-Valenzuela L, Goycoolea FM, et al. Astaxanthin: a review of its chemistry and applications. Crit Rev Food Sci Nutr. 2006;46(2):185-96.
4. Hussein G, Sankawa U, Goto H, Matsumoto K, Watanabe H. Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod. 2006 Mar;69(3):443-9.

Vitamin D May Lower Multiple Sclerosis Risk

image

Increasing vitamin D intake may reduce the risk of developing multiple sclerosis (MS), according to a recent Harvard study.* In a study of 257 US military personnel with MS and 51 healthy control subjects, white adults in the highest quintile of serum vitamin D levels had a 62% lower risk of developing MS than those in the lowest quintile. Among white/non-Hispanics, the risk of MS dropped 41% for every 50-nmol/L increase of 25-hydroxyvitamin D in the blood. No association between serum levels of 25-hydroxyvitamin D and MS risk was noted for African-Americans or Hispanics, who had lower levels of this form of vitamin D in their blood compared to whites.

The researchers called for further investigation into vitamin D’s protective role against multiple sclerosis.

—Dale Kiefer

Reference

* Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006 Dec 20;296(23):2832-8.

Creatine Improves Health, Extends Life Span in Mice

Creatine increases life span and enhances cognitive function in mice, according to a recent report from German scientists.1

Used clinically to enhance endurance and improve muscle strength,2,3 creatine and its ability to increase energy utilization and reduce oxidative damage in the nervous system has recently drawn attention from scientists seeking cures for Huntington’s disease, muscular dystrophy, and Alzheimer’s disease.4-6

Due to its “marked neuroprotective effect” in rodent models of these and other diseases, as well as similar processes underlying aging and neurological disorders, the German researchers wondered whether creatine might also offer anti-aging benefits.1 They found that mice fed creatine lived an average of 9% longer than control subjects, performed better in neurobehavioral tests, and exhibited less accumulation of lipofuscin, a lipid pigment associated with aging.1,7

“[Creatine] may be a promising food supplement to promote healthy human aging,” the scientists concluded.1

—Dale Kiefer

Reference

1. Bender A, Beckers J, Schneider I, et al. Creatine improves health and survival of mice. Neurobiol Aging. 2007 Apr 6; [Epub ahead of print].
2. Ayoama R, Hiruma E, Sasaki H. Effects of creatine loading on muscular strength and endurance of female softball players. J Sports Med Phys Fitness. 2003 Dec;43(4):481-7.
3. Olsen S, Aagaard P, Kadi F, et al. Creatine supplementation augments the increase in satellite cell and myonuclei number in human skeletal muscle induced by strength training. J Physiol. 2006 Jun 1;573(Pt 2):525-34.
4. Burklen TS, Schlattner U, Homayouni R, et al. The Creatine Kinase/Creatine Connection to Alzheimer’s Disease: CK-Inactivation, APP-CK Complexes and Focal Creatine Deposits. J Biomed Biotechnol. 2006;2006(3):35936.
5. Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2’dG. Neurology. 2006 Jan 24;66(2):250-2.
6. Pearlman JP, Fielding RA. Creatine monohydrate as a therapeutic aid in muscular dystrophy. Nutr Rev. 2006 Feb;64(2 Pt 1):80-8. 7. Riga S, Riga D, Schneider F, Halalau F. Processing, lysis, and elimination of brain lipopigments in rejuvenation therapies. Ann N Y Acad Sci. 2006 May;1067:383-7.

Low-Dose DHA Modestly Lowers Blood Pressure

image

British researchers have demonstrated that low doses of docosahexaenoic acid (DHA), an omega-3 fatty acid found in algae and fish oil, modestly reduce blood pressure.* Previous studies have associated intake of omega-3 fatty acids with a decreased risk of death from heart attack.

In a randomized, double-blind, placebo-controlled trial of 38 healthy men and women aged 40-65, the subjects received either 0.7 grams of DHA or placebo daily for three months. After a four-month washout period, the treatments were switched. When subjects took DHA, their diastolic blood pressure fell by 3.3 mm Hg and their heart rate dropped by 2.1 beats per minute.

“The results indicate that a moderate increase in the daily intake of DHA . . . lowers diastolic blood pressure,” the researchers concluded.

—Dale Kiefer

Reference

* Theobald HE, Goodall AH, Sattar N, Talbot DC, Chowienczyk PJ, Sanders TA. Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women. J Nutr. 2007 Apr;137(4):973-8.

“Stable” Atherothrombosis Still Imperils Health

image

Patients with stable atherothrombosis are at an alarmingly high risk of death or cardiovascular disease, according to the first study to document the effects of atherothrombosis in outpatients.1,2 Atherothrombosis, which occurs when a blood clot (thrombus) forms on a ruptured plaque (atheroma) in a blood vessel wall, is the common link among heart attack, stroke, and peripheral arterial disease.

Data from 68,000 outpatients in 44 countries showed that despite appearing and feeling healthy in many cases, patients with established disease had roughly a one-in-seven chance of death, suffering a heart attack or stroke, or being hospitalized due to cardiovascular disease within one year. Patients with peripheral arterial disease (clogged arteries in the legs or abdomen) were at even greater risk, with a 22% one-year risk of suffering a major cardiovascular event. Those with atherothrombotic disease in three or more locations had a 28% risk of major adverse cardiovascular events.

—Dale Kiefer

Reference

1. Available at: http://www.reachregistry.org. Accessed March 21, 2007.
2. Ohman EM, Bhatt DL, Steg PG, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006 Apr;151(4):786.e1-10.

Blueberries May Help Prevent Colon Cancer

image

A compound in blueberries protected laboratory animals from colon cancer, according to presenters at a national meeting of the American Chemical Society.* Known as pterostilbene, the compound is an antioxidant similar to resveratrol that could be developed into a preventive nutritional supplement.

After rats were given a known carcinogen to induce colon cancer, half were supplemented with pterostilbene. After eight weeks, the supplemented animals had 57% fewer pre-cancerous colon lesions than the control rats, as well as reduced colon cell proliferation and expression of genes involved in inflammation, which is a risk factor for the disease.

This study, the first to demonstrate pterostilbene’s ability to combat colon cancer, “underscores the need to include more berries in the diet, especially blueberries,” the researchers concluded.

—Dayna Dye

Reference

* Available at: http://www.medicalnewstoday.com/medicalnews.php?newsid=66123. Accessed April 9, 2007.

Continued on Page 2 of 2